Recent reports generated by WHAM (Women’s Health Access Matters, a nonprofit organization focused on demonstrating the economic imperative of women’s health research) highlighted the discrepancies in investment in women’s health research which is, in general, severely underfunded. ...
Achieving precision medicine depends on federal resources to de-risk bold development, prototype impactful technologies, advance manufacturing, and put public good and public health on solid economic ground....
Real-world evidence (RWE)-based approaches will increasingly influence clinical decision-making as real-world data (RWD) analysis methods advance, along with expanding acquisition, aggregation, and harmonization of RWD from traditional and novel sources....
Gene-modified cell therapies – often also referred to as ex vivo gene therapies - consist of specific cells that are genetically modified outside the body being administered as a therapeutic in order to help the patient fight a particular disease. ...
The biggest winner of COVID was liquid biopsy (LB), as interventional surgeries for biopsies simply weren’t happening during much of the pandemic....
We are in an era when the volume of healthcare data is growing at lightning speed but our ability to gain insights from that data for improved health outcomes remains far behind....
Large-scale omics initiatives (i.e., population studies) that generate and collect human genomic data are evolving rapidly across the globe in both the private and public sectors....
Ten years ago the first child received CAR T-cell therapy to treat acute lymphoblastic leukemia, the most common childhood cancer. Today she is 10 years cancer free....
Clinical implementation of pharmacogenetic testing is no longer held back primarily by a lack of evidence supporting its use but remains relatively rare for practical reasons....
PMWC January 25-27, 2023’s Conference theme, "COVID-19 Learnings for Precision Medicine: Collaboration = Breakthroughs"...
